ELISA for determination of the haptoglobin phenotype

Clinical Chemistry

Volumn 50, Issue 11, 2004, Pages 2148-2150

  Levy, Nina S ^a   Levy, Andrew P ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HAPTOGLOBIN;

ANALYTIC METHOD; ARTICLE; CARDIOVASCULAR DISEASE; CHROMOSOME 6Q; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE LOCUS; GENETIC POLYMORPHISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS;

ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; HAPTOGLOBINS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MICE; MICE, INBRED C57BL; PEPTIDE LIBRARY; PHENOTYPE;

EID: 7044224744     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.038547     Document Type: Article

References (21)

1. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996;42:1589-600.
2. Nakhoul F, Marsh S, Hochberg I, Leibu R, Miller BP, Levy AP. Haptoglobin phenotype and diabetic retinopathy [Research Letter]. JAMA 2000;284:1244-5.
3. Levy AP, Roguin A, Marsh S, Nakhoul FM, Herer P, Hochberg I, et al. Haptoglobin phenotype and vascular complications in diabetes [Research Letter]. New Eng J Med 2000;343:969-70.
4. Roguin A, Hochberg I, Nikolsky E, Markiewicz W, Meisel SR, Hir J, et al. Haptoglobin phenotype as a predictor of restenosis after PTCA. Am J Card 2001;87:330-2.
5. Nakhoul FM, Zoabi R, Kantor Y, Zoabi M, Hochberg I, Leibu R, et al. Haptoglobin phenotype and diabetic nephropathy. Diabetologia 2001;44:602-4.
6. Hochberg I, Roguin A, Nikolsky E, Chanderashekhar PV, Cohen S, Levy AP. Haptoglobin phenotype and coronary artery collaterals in diabetic patients. Atherosclerosis 2002;161:441-6.
7. Roguin A, Ribichini F, Ferraro V, Matullo G, Herer P, Wijns W, et al. Haptoglobin phenotype and the risk of restenosis after coronary artery stent implantation. Am J Cardiol 2002;89:806-10.
8. Levy AP, Hochberg I, Jablonski K, Resnick H, Best L, Lee ET, et al. Haptoglobin phenotype and the risk of cardiovascular disease in individuals with diabetes: The Strong Heart Study. J Am Coll Cardiol 2002;40:1984-90.
9. Roguin A, Koch W, Kastrati A, Aronson D, Schomig A, Levy AP. Haptoglobin genotype is predictive of major adverse cardiac events in the one year period after PTCA in individuals with diabetes. Diabetes Care 2003;26:2628-31.
10. Suleiman M, Kapeliovich MR, Roguin A, Aaronson D, Meisel SR, Shochat M, et al. Haptoglobin phenotype and mortality in the 30 day period following acute myocardial infarction. Diabetes Care 2003;26:2699-700.
11. Levy AP, Larson MG, Corey D, Lotan R, Vita JA, Benjamin EJ. Haptoglobin phenotype and prevalent coronary heart disease in the Framingham Offspring Cohort. Atherosclerosis 2004;172:361-5.
12. Levy AP, Friedenberg P, Lotan R, Ouyang P, Triputti M, Higginson L, et al. The effect of vitamin therapy on the progression of coronary artery atherosclerosis varies by haptoglobin type in post-menopausal women. Diabetes Care 2004;27:925-30.
13. Burbea Z, Nakhoul F, Rosenberg S, Zoabi R, Skorecki K, Hochberg I, et al. Haptoglobin phenotype role in end-stage kidney. Nephron Exp Nephrol 2004;97:71-6.
14. Frank M, Lache O, Enav B, Szafranek T, Levy NS, Ricklis RM, et al. Structure/function analysis of the anti-oxidant properties of haptoglobin. Blood 2001;98:3693-8.
15. Asleh R, Marsh S, Shiltruck M, Binah O, Guetta J, Lejbkowicz F, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 2003;92:1193-200.
16. Delanghe JR, Allcock K, Langlois M, Claeys L, De Buyzere M. Fast determination of haptoglobin phenotype and calculation of hemoglobin binding capacity using high pressure gel permeation chromatography. Clin Chim Acta 2000;291:43-51.
17. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schomig A, et al. Genotyping of common haptoglobin polymorphism Hp 1/2 based on the polymerase chain reaction. Clin Chem 2002;48:1377-82.
18. Benhar I, Reiter Y. Phage display of single-chain antibody (scFv) constructs. Curr Protoc Immunol 2002;48:59-87.
19. Denkberg G, Lev A, Eisenbach L, Benhar I, Reiter Y. Selective targetting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J Immunol 2003;171:2197-207.
20. Dati F, Schumann G, Thomas L, Aguzzi F, Baudner S, Bienvenu J, et al. Consensus of a group of professional societies and diagnostics companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP reference material (CRM 470). Eur J Clin Chem Clin Biochem 1996;34:517-20.
21. Kasvosve I, Gomo ZAR, Gangaidzo IT, Mvundura E, Saungweme T, Moyo VM, et al. Reference range of serum haptoglobin is haptoglobin phenotype-dependent in blacks. Clin Chim Acta 2000;296:163-70.